Biogen has welcomed receiving the first positive reimbursement decision to come from the BeNeLuxA partnership, the coalition of European countries seeking to improve access to medicines by working together to secure joint pricing and reimbursement decisions, among other things. The company says that the process was collaborative and constructive, although not without its challenges thanks to differences in local laws.
Two BeNeLuxA partners, Belgium and the Netherlands, agreed to reimburse Biogen’s orphan drug Spinraza (nusinersen) following joint health technology assessment...








